Related Experiment Video
Updated: Aug 13, 2026
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Hematological Questions in Personalized Management of COVID-19 Vaccination
Tingting Wu1, Junying Li1, Yu Hu1
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Insights
COVID-19 vaccines reduce severe illness, but rare hematologic adverse events like thrombosis and thrombocytopenia occur. Safety and efficacy in patients with blood disorders require careful consideration.
Area of Science:
- Hematology
- Immunology
- Infectious Diseases
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, has led to widespread vaccination efforts.
- While vaccines significantly reduce morbidity and mortality, various adverse effects, including hematological events, have been reported.
- Concerns exist regarding vaccine safety in individuals with pre-existing hematologic conditions and hematological tumors.
Purpose of the Study:
- To review reported hematological adverse events following COVID-19 vaccination.
- To discuss the safety and efficacy of COVID-19 vaccination in patients with hematological disorders.
Main Methods:
- Literature review of reported hematological events post-COVID-19 vaccination.
- Analysis of existing data on vaccination in patients with hematological conditions.
Main Results:
- Reported hematological events include thromboembolic events, thrombocytopenia, and bleeding.
- Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a recognized syndrome.
- Data on vaccine efficacy and safety in hematologic patients is still emerging.
Conclusions:
- Hematological adverse events, though rare, are a noted concern with COVID-19 vaccines.
- Further research is needed to establish definitive vaccine safety and efficacy profiles for patients with hematological disorders.
Abstract:
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been causing a worldwide pandemic since 2019. Many vaccines have been manufactured and have shown promising results in reducing disease morbidity and mortality. However, a variety of vaccine-related adverse effects, including hematological events, have been reported, such as thromboembolic events, thrombocytopenia, and bleeding. Moreover, a new syndrome, vaccine-induced immune thrombotic thrombocytopenia, following vaccination against COVID-19 has been recognized. These hematologic side effects have also raised concerns about SARS-CoV-2 vaccination in patients with preexisting hematologic conditions. Patients with hematological tumors are at a higher risk of severe SARS-CoV-2 infection, and the efficacy and safety of vaccination in this group remain uncertain and have raised attention. In this review, we discuss the hematological events following COVID-19 vaccination and vaccination in patients with hematological disorders.
More Related Videos
06:03Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
Published on: September 20, 2024
04:43COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah
Published on: June 24, 2025